Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PH300
- Development stage
- Preclinical
- Lead developer
- Botamedi
- Modality
- Small Molecules
- Administration
- Injectable
01
Overview
PH300 (also known as PH300 Injectable) is a preclinical-stage injectable small molecule therapeutic being developed by Botamedi Inc. for the treatment of systemic inflammations. The drug is derived from SEANOL®, a proprietary marine phytochemical extract obtained from the brown algae *Ecklonia cava*, which is characterized by a high concentration of phlorotannins (eckols). PH300 is designed to leverage the anti-inflammatory and multipotent pharmacological activities of these marine polyphenols. While the specific molecular targets have not been disclosed, the candidate is part of a pipeline focused on marine-derived botanical medicines for chronic and inflammatory conditions.
Beyond the preview
Go deeper on PH300.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PH300.